Statements

People with extensively drug-resistant tuberculosis (XDR-TB) and others with expanded drug resistance have few options and face long, difficult treatment with older, less-effective, and more toxic drugs. In response to this emergency, front-line clinical providers, civil society organizations, and impacted…

Contact: Natalie Shure, natalie.shure@treatmentactiongroup.org New York City, September 3, 2024 — We’re pleased to announce the launch of www.globaltbcab.org, a new website that tells about the work of the Global Tuberculosis Community Advisory Board (TB CAB) — an international network…

CONTACT: Natalie Shure, natalie.shure@treatmentactiongroup.org December 21, 2023 – This week, the Statens Serum Institut (SSI) and IAVI shared topline results of the phase IIb trial of H56:IC31, a subunit TB vaccine developed by SSI in Denmark consisting of four Mycobacterium…

CONTACT: Lindsay McKenna, Treatment Action Group, Lindsay.McKenna@treatmentactiongroup.org; Patrick Agbassi, TB CAB, ayjpatrick@gmail.com November 16, 2022 – Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB) welcome the clinical trials results recently published and presented during the…

CONTACT: TB CAB chair, Patrick Agbassi: ayjpatrick@gmail.com 14 July 2020 – The Global Tuberculosis Community Advisory Board (TB CAB) welcomes the Johnson & Johnson (J&J) and Stop TB Partnership Global Drug Facility (GDF) announcement regarding the reduction in price of…

For comments, please write to TB CAB co-chairs: Carolina Moran Jara: kromoran28@gmail.com; Patrick Agbassi: ayjpatrick@gmail.com 18 May, 2019 — In March 2019, the United States Food and Drug Administration (FDA) accepted a new drug application (NDA) for pretomanid, a drug…

5 April, 2019 –The Global TB Community Advisory Board (Global TB CAB) wishes to submit the following statement to the High-level consultation on accelerating the development of the M72/AS01E tuberculosis vaccine candidate convened by the World Health Organization (WHO) on…

Global TB CAB welcomes confirmation of safety of using bedaquiline and delamanid together, urges uptake. March 12, 2019 – The Global TB Community Advisory Board (TB CAB) welcomes the important finding from the AIDS Clinical Trials Group Deliberate Trial that…

The WHO, Ministries of Health and Finance, donors, implementers, technical assistance providers, civil society, and communities must work together to ensure rapid implementation. 17 August 2018 – The Global Tuberculosis Community Advisory Board (TB CAB) and Treatment Action Group (TAG)…

The TB CAB reiterates its request for Johnson & Johnson to commit to a global price for bedaquiline that is no higher than US$32 per month. July 24, 2018 – The Global Tuberculosis Community Advisory Board (TB CAB) acknowledges the…